volume of 80-100 mm 3. At this point, mice received intravenous injections of either various doses of effector cells alone, 400 #g mAb 9.2.27 alone or a combination of both. Tumor size was measured twice weekly with a graduated calimeter, for a total time of 6 wk after tumor inoculation; animals with large tumors were sacrificed earlier. Tumorfree animals were observed a total of 8 wk to assure that no tumor growth occurred.
Tumor volume was calculated by the formula ~dld2dJ2, in which d is the diameter of the tumor.
Antibodies. mAb 9.2.27 originally produced in this laboratory was shown to be of IgG2a isotype and directed against a chondroitin sulfate proteoglycan preferentially expressed on human melanoma cells (8) . IgG was purified from ascitic fluid by precipitation with 50% ammonium sulfate and protein A-Sepharose affinity chromatography (Sigma Chemical Co., St. Louis, MO) according to the method of Ey et al. (9) . The following antibodies against NK cell markers were used: rabbit anti-asialo GMI antiserum (Wako Chemicals, Dallas, TX); anti-Qa5 and anti-Lyt-6.2 antisera, kindly provided by Dr. U. Hammerling (Sloan-Kettering Institute for Cancer Research, New York); and anti-NK 1.1, kindly provided by Dr. S. Pollack, (University of Washington, Seattle). Nontoxic rabbit serum (Accurate Chemical & Scientific Corporation, Westbury, NY) served as a source of complement.
Treatment of Cells With Antibody and Complement.
Mouse spleen cells (107/ml) were incubated for 30 min at room temperature with antisera diluted 1:20 to 1:50 in RPMI 1640 medium. The cells were centrifuged; the supernatant containing unbound antibody was discarded; and the cells resuspended in complement diluted 1:10 in RPMI 1640 medium and incubated at 37°C for 45 min. Cells were washed twice in ice-cold medium and stored on ice before assay for cytotoxicity.
In Vitro Cytotoxicity Assays. Mouse mononuclear splenocytes, isolated by Hypaque Ficoll gradient centrifugation (LSM; Litton Bionetics Inc., Charleston, SC), were used as effector cells (7) . BALB/c and C57BL/6 splenocytes served as normal effector cells whereas splenocytes from athymic BALB/c nu/nu mice were used as the source of T cell-deficient effector cells. Splenocytes from C57BL/6 mice with the homozygous beige mutation (Vivarium, Scripps Clinic and Research Foundation) were used as a source of NK-deficient effector cells. Cloned cells with NK activity (NKB61B 10) were grown as described earlier (10) . In vitro cytotoxicity of splenocytes against tumor cells was assayed in a 5~Cr release assay as previously described (7, 10) . Briefly, tumor target cells were labeled with 51Cr and plated in 96-well round-bottom tissue culture plates (Costar, Data Packaging, Cambridge, MA) at 104 (K562, Yac-1) or at 5 × 103 (M21) cells per well. Effector cells were added at various target/effector ratios. Replicate wells in triplicate were incubated at 37°C in CO2 for 4 h (K562, Yac-1) or 16 h (M21). Cytolysis was calculated as: percent lysis --[(experimental release -spontaneous release)/(maximum release -spontaneous release)] × 100.
To test for antibody-dependent, cell-mediated lysis (ADCC), we incubated tumor target cells with 50 ~1 per well of 9.2.27 antibody (ascites diluted 1:100) for 1 h at 37°C. The plates were centrifuged for 2 min, the supernatant fluids containing unbound antibody were discarded, and effector cells were added.
Results

Melanoma Growth in Nude Mice Is Influenced by a Component that Is Sensitive to
Anti-asialoGM1 Serum. In previous experiments (7), we had observed that the growth of M21 melanoma cells in nude mice can be suppressed by the simultaneous injection of mAb 9.2.27 specific for M21 and splenocytes at the time of tumor inoculation. We suspected that tumor suppression was caused by a cellmediated mechanism and that the effector cells involved were NK cells, since this cell type expresses ADCC activity. To examine the possibility that M21 melanoma growth in nude mice is under the control of NK cells, we rendered BALB/c nude mice NK deficient by injection with anti-asialo GM1 serum (11, 12) . 24 h later, groups of untreated or anti-asialo GM~-treated mice were inoculated subcutaneously with either 2.5 x 106 or 5 x 106 M21 cells. After 20 d, all mice that received a dose of 5 x 106 tumor cells showed tumor growth. The mean tumor volume in this anti-asialo GM~-treated group was similar to the one in the untreated animals, i.e., 220 mm 3 vs. 190 mm 3 (Table I) . A pronounced effect of the anti-asiaio GM1 treatment was seen, however, in animals that received 2.5 x 106 melanoma cells: All five mice that were treated with anti-asialo GMI developed tumors, whereas only one of five animals in the untreated group exhibited tumor growth. This result demonstrates that treatment with anti-asialo GM~ greatly facilitates the growth of M21 melanoma cells in nude mice in the absence of injected antibody. Since in control experiments, we ascertained that injection of anti-asia|o GMt very efficiently eliminates NK activity, this suggested that NK cells may indeed play a role in the suppression of melanoma growth in nude mice.
Progressively Growing M21 Tumors Are Eliminated in Nude Mice by Injection of mAb 9.2.27 and Mononuclear Splenocytes from Normal Mice. We previously observed (7) that M21 melanoma tumor growth in nude mice could be inhibited when mononuclear mouse splenocytes and mAb 9.2.27, either alone or in combination, were injected within 1 d after tumor cell inoculation. Based on these findings, we now examined whether a combination of mAb 9.2.27 and cell populations with NK activity could eliminate well established, growing M21 melanoma tumors in nude mice. Groups of BALB/c nude mice (Table II) with 2-wk-old subcutaneous melanoma (mean volume, 90 mm 3) were either left untreated (Table II , group 1), or were injected intravenously with mAb 9.2.27 IgG (Table II , group 2), BALB/c mononuclear splenocytes (Table II, group 3) , or a combination of antibody and splenocytes (Table II, group 4). 4 wk after injection, 7 of 10 animals in the group that received both antibody and splenocytes (Table II , group 4) were tumor free. In contrast, all other mice exhibited large tumors, with the exception of one animal in the group that received splenocytes only (Table II, 
Cells Responsible for Antibody-induced Tumor Regression Are Present in Splenocytes of Tumor-free or Tumor-bearing Nude Mice.
Since nude mice lack T cells, but the splenocytes from normal mice do not, it was possible that the effects observed were due to T cells. To examine this possibility, we injected tumor-bearing mice with mononuclear splenocytes from T cell-deficient nude mice. In groups 5, 6, and 7 (Table II) , a combination of mAb 9.2.27 with splenocytes from BALB/c nude mice eliminated the growing tumors as effectively as the cells from normal BALB/c mice. Six of nine animals receiving antibody and splenocytes from nude mice (Table II, group 7) were tumor-free 4 wk after injection and the tumors in the remaining animals were much smaller than in the control group (149 + 41 mm'~). In contrast, eight of nine mice treated with effector cells only (Table II,  group 6 ) and all nine animals injected with antibody only (Table II, suggests that the presence of T cells in normal splenocytes is not required for the elimination of tumors. Next, it was important to explore whether the effector cells responsible for tumor regression are also present in splenocytes of tumorbearing nude mice or only in animals that are free of M21 tumors. In groups 8, 9, and 10 (Table II) (Table I) . Second, T cell-deficient nude mice reject the tumors in both the absence or presence of mAb 9.2.27 (Tables I and  II) . To explore this possibility further, we injected BALB/c nude mice with M21 tumor cells as before. After 14 d, when the tumors had a mean volume of 90 mm 3, mice were injected with 2 × 107 splenocytes, some of which had been treated with anti-asialo GMI and complement. Mice also received the usual dose of mAb 9.2.27. Only three of nine animals that received untreated splenocytes together with mAb 9.2.27 (Table III, group 2) showed very limited tumor growth after 4 wk. In contrast, all mice that received splenocytes treated with anti-asialo GM~ and complement showed substantial tumor growth (Table III,  group 3) , essentially the same as that of the control group (Table III, group 1) . These results indicate that the effector cells responsible for tumor regression carry the asialo GM~ cell surface antigen, and suggest that they may be NK cells. To further test this conclusion, splenocytes from genetically NK-deficient mice carrying the homozygous beige mutation (13, 14) were also transplanted in tumor-bearing hosts. Specifically, C57BL/6 nude mice with progressively growing M21 tumors were injected with mAb 9.2.27 together with splenocytes from either normal C57BL/6 mice or C57BL/6 beige mice. None of the animals that received normal C57BL/6 splenocytes and antibody showed tumor growth after 4 wk (Table III , group 5), as was expected from the experiments with splenocytes from normal BALB/c mice (Table II, group 4). In contrast, animals that received mAb 9.2.27 and splenocytes from C57BL/6 beige mice experienced high tumor incidence (Table III, group 6) , showing that the cell type responsible for tumor rejection is absent in beige mice and is therefore likely associated with NK activity. To further substantiate the conclusion that NK cells are responsible for tumor regression, we injected C57BL/6 nude mice that had established M21 tumors with the cloned NK cell line NKB61B10. In groups 7, 8, and 9 (Table  III) , a single dose of 2 × l0 s NKB61B10 cells, i.e., a dose only 1A0th that of the splenocytes used in the other experiments, resulted in a strong suppression of tumor size (~70%), particularly in those mice that received antibody as well as NK cells. However, tumors were not completely eliminated, probably because of the uncommonly large size of the tumors at the onset of the experiment (mean volume, 185 mm3).
M21 Melanoma Cells Are Lysed by Effector Cells with NK Activity in the Presence ofmAb 9.2.27.
The experiments so far presented point to the importance of the presence of both effector cells with NK activity and specific antibody for the Data are given for day 28 after antibody and cell injection, i.e., 42 d after tumor inoculation. Tumor-free animals were observed for an additional 28 d. * Mean tumor size at the onset of the experiments was 90 mms at day 14 after tumor inoculation. 2
x 107 splenocytes were injected. * Mean tumor size at the onset of the experiment was 185 mms at day 14 after tumor inoculation. 2 x 106 NKB61B10 were injected.
elimination of an established tumor. Since it is known (15) (16) (17) (18) (19) that NK cells are able to perform ADCC, we examined whether M21 melanoma cells were lysed by mAb 9.2.27 and effector cells with NK activity. To this end, BALB/c mononuclear splenocytes, mixed with M21 melanoma target cells, were assayed for their cytolytic activity in the absence and presence of mAb 9.2.27 in 5~Cr release assays. We found that the effector cells caused 25% cytolysis in the absence of antibody (Fig. 1) . After preincubation of the target cells with mAb 9.2.27, the cytotoxicity increased to 38%. The same effector cell population also showed lysis of the NK-sensitive YAC-1 target. The elimination of cells with NK activity by pretreatment of splenocytes with anti-asialo GM~ serum and complement resulted in a marked reduction of cytotoxicity against M21 cells, both in the presence and absence of mAb 9.2.27. At the same time, the anti-asialo GM1-treated effector cells were no longer able to lyse YAC-1 target cells, indicating that NK activity was indeed eliminated by this treatment. To further substantiate the conclusion that cells with NK activity were the effectors in this ADCC reaction, we used other antibodies that are specific for NK cells, i.e., anti-Qa5 and anti-NK1.1 (20) (21) (22) (23) (24) . In addition, effector cells from NK-deficient C57BL/6 beige mice (13, 14) were tested. The data in Fig. 2 resulted in a complete suppression of cytotoxicity of both YAC-1 and M21, regardless of the presence of mAb 9.2.27. In addition, C57BL/6 beige effector cells did not mediate an efficient cytotoxicity in these assays. These results strongly support the conclusion that cells with NK activity are indeed responsible for the antibody-dependent and antibody-independent cytolysis of M21 tumors. Discussion Our results show that the eradication of well established melanomas in athymic mice using tumor-specific antibody requires the simultaneous injection of a relatively large number of mononuclear splenocytes. Neither splenocytes nor antibody alone achieved significant tumor regression. The cells responsible for tumor elimination are probably cells with NK activity: they are present in splenocytes of T cell-deficient nude mice, and cloned NK cells are similarly able to suppress tumor growth. Moreover, the effector cells were absent in splenocytes of NK-deficient beige mice and could be eliminated by injection of mice with anti-asialo GM1 antiserum, which is known to eliminate NK activity. Previous studies (20, (25) (26) (27) suggested that there may be a degree of heterogeneity within mouse NK cells, not only in cell surface markers but also in responsiveness to the regulatory influences of interferon and interleukin 2. It is therefore possible that the ceils responsible for tumor regression are heterogeneous. Our observation that clone NKB61B10 was not quite as effective as normal splenocytes may support this possibility, especially since this clone very effectively prevents the rejection of bone marrow allografts and protects against radiation-induced leukemia (28) . A more precise definition of the cell type responsible for tumor regression would have been possible using other NK-specific reagents, like anti- Qa5 and anti-NKl.1 antisera, which are reactive with C57BL/6 NK cells but have little reactivity with other cell types, like T cells, natural cytotoxic cells, or monocytes (20, 21, 23, 27, 29) . The limited amounts of these antisera available, however, precluded their in vivo use. We therefore demonstrated in vitro that both antibody-dependent and antibody-independent cell-mediated lysis of M21 melanoma targets is inhibited not only by anti-asialo GM~ but also by anti-Qa5 and anti-NK1.1. The ability of anti-NK 1.1 to eliminate NK cells in vivo and in vitro had been previously demonstrated by the work of Pollack (23, 24) . Our results, therefore, strongly support the conclusion that both, antibody-dependent and antibody-independent in vitro lysis and in vivo elimination of tumor ceils are functions of effector cells with NK activity. This conclusion is in full agreement with previous results demonstrating that cloned murine cell lines (10) with NK activity not only restored the ability of NK-deficient mice to suppress the growth of the murine melanoma B16, but also decreased the incidence of radiationi YaC induced leukemias (28) . Moreover, the ability to reject bone marrow grafts is also restored by injection of cloned NK cells into NK-deficient mice. Interestingly, the specificity of marrow graft rejection depends on IgG antibody present in the graft recipient and specific for the bone marrow transplant (28, 30) . The acute rejection of bone marrow grafts by NK cells is, therefore, due to an antibody-dependent cytotoxic reaction, very similar to the rejection of M21 melanoma tumors induced by mAb 9.2.27 and NK cells. It is interesting that the injection of the tumor-specific mAb 9.2.27 into tumorbearing nude mice is not sufficient to ca'use optimal tumor rejection, especially since such animals have a high level of NK activity. The explanation we favor is that the number of NK cells in the host is insufficient to cause tumor rejection. Another possibility is that host NK cells are blocked in their interaction with the mAb by circulating serum factors that inhibit their action; however, our experiments with spleen cells from tumor-bearing mice argue against this possibility. It may be important that antibody and effector cells be injected simultaneously so that the antibody can bind to the effectors, thereby "arming" them. This antibody-effector cell interaction may facilitate the targeting of effector cells to the tumor in a more efficient way. Previously (7), we noticed that the simultaneous injection of tumor cells and effector cells armed with antibody by conjugation with polyethylene glycol very efficiently suppresses in vivo tumor growth. Taken together, these results may suggest a novel approach for the treatment of tumors that makes use of two powerful tools, tumor-specific mAb and cytolytic effector lymphocytes.
Summary
The simultaneous injection of monoclonal antibody 9.2.27, directed against a chondroitin sulfate proteoglycan preferentially expressed on human melanoma cells, and 2 x 107 mononuclear splenocytes, eradicated established, progressively growing human melanoma tumors in nude mice. Neither splenocytes nor antibody alone achieved significant tumor regression. The cells responsible for tumor elimination are most likely natural killer (NK) cells: they are present in splenocytes of T cell-deficient nude mice, and cloned cells with NK activity are able to suppress tumor growth. Moreover, splenocytes treated with anti-asialo GM~ and complement or harvested from NK-deficient C57BL/6 beige mice did not cause tumor rejection. Furthermore, treatment of BALB/c nude mice just before injection with anti-asialo GM1 antiserum, which is known to eliminate NK activity in vivo, resulted in better tumor growth. In addition, evidence is presented that cells with NK activity are probably the effectors responsible for melanoma target cell lysis in vitro: Antibody-dependem and -independent cell-mediated lysis of M21 melanoma cells was suppressed when splenocytes were preincubated with J complement and antibodies specific for cell surface antigens of NK cells, i.e., anti-asialo GM~, anti-Qa5, and anti-NKl.1. Moreover, splenocytes of C57BL/6 beige mice were not able to lyse M21 cells in vitro. These results strongly support the conclusion that cells with NK activity are indeed responsible for the antibodydependent destruction of M21 melanoma cells in vivo and in vitro.
